메뉴 건너뛰기




Volumn 40, Issue 11, 2017, Pages 1425-1432

Type 2 diabetes in the real world: The elusive nature of glycemic control

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN;

EID: 85033225595     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-1974     Document Type: Article
Times cited : (211)

References (55)
  • 1
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
    • UK Prospective Diabetes Study (UKPDS) Group
    • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
    • (1998) Lancet , vol.352 , pp. 837-853
  • 2
    • 0027370108 scopus 로고
    • The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
    • The Diabetes Control and Complications Trial ResearchGroup
    • The Diabetes Control and Complications Trial ResearchGroup. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
    • (1993) N Engl J Med , vol.329 , pp. 977-986
  • 3
    • 0032958316 scopus 로고    scopus 로고
    • Design and implementation of a long-term follow-up of the Diabetes Control and Complications Trial cohort
    • Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC)
    • Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC). Design and implementation of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99-111
    • (1999) Diabetes Care , vol.22 , pp. 99-111
  • 4
    • 77649329576 scopus 로고    scopus 로고
    • Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
    • Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800-811
    • (2010) N Engl J Med , vol.362 , pp. 800-811
    • Selvin, E.1    Steffes, M.W.2    Zhu, H.3
  • 5
    • 78650345164 scopus 로고    scopus 로고
    • Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes
    • Selvin E, Ning Y, Steffes MW, et al. Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes 2011;60:298-305
    • (2011) Diabetes , vol.60 , pp. 298-305
    • Selvin, E.1    Ning, Y.2    Steffes, M.W.3
  • 6
    • 84919999219 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach
    • Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149
    • (2015) Diabetes Care , vol.38 , pp. 140-149
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 7
    • 84906978168 scopus 로고    scopus 로고
    • Centers for Disease Control and Prevention. Atlanta, GA, U. S. Department of Health and Human Services. Accessed 10 January 2016
    • Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014 [Internet], 2014. Atlanta, GA, U. S. Department of Health and Human Services. Available fromhttp://www. cdc. gov/diabetes/pubs/statsreport14/ national-diabetes-report-web. pdf. Accessed 10 January 2016
    • (2014) National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014 [Internet]
  • 10
    • 84988575514 scopus 로고    scopus 로고
    • National Committee for Quality Assurance. Washington, DC, National Committee for Quality Assurance. Accessed 5 July 2016
    • National Committee for Quality Assurance. The State of Health Care Quality Report 2015 [Internet], 2015. Washington, DC, National Committee for Quality Assurance. Available for download from http://store. ncqa. org/index. php/catalog/ product/view/id/2341/s/2015-state-of-healthcare-quality-report/. Accessed 5 July 2016
    • (2015) The State of Health Care Quality Report 2015 [Internet]
  • 11
    • 85033229775 scopus 로고    scopus 로고
    • Centers for Disease Control and Prevention. Accessed 8 September 2017
    • Centers for Disease Control and Prevention. PowerPoint slides on diabetes: Long-term trends in diabetes [Internet], 2017. Available from https://www. cdc. gov/diabetes/data/center/ slides. html. Accessed 8 September 2017
    • (2017) PowerPoint Slides on Diabetes: Long-term Trends in Diabetes [Internet]
  • 12
    • 77951700065 scopus 로고    scopus 로고
    • U. S. Food andDrug Administration. Accessed 12 July 2016
    • U. S. Food andDrug Administration. DrugsFDA: FDA approved drug products [Internet]. Available from https://www. Accessdata. fda. gov/scripts/ cder/drugsatfda/. Accessed 12 July 2016
    • DrugsFDA: FDA Approved Drug Products [Internet]
  • 14
    • 80053569496 scopus 로고    scopus 로고
    • Participation in a clinical trial enhances adherence and persistence to treatment: A retrospective cohort study
    • van Onzenoort HA, Menger FE, Neef C, et al. Participation in a clinical trial enhances adherence and persistence to treatment: A retrospective cohort study. Hypertension 2011;58:573-578
    • (2011) Hypertension , vol.58 , pp. 573-578
    • Van Onzenoort, H.A.1    Menger, F.E.2    Neef, C.3
  • 15
    • 11444261579 scopus 로고    scopus 로고
    • External validity of randomised controlled trials: To whom do the results of this trial apply
    • Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply" Lancet 2005;365:82-93
    • (2005) Lancet , vol.365 , pp. 82-93
    • Rothwell, P.M.1
  • 16
    • 85033230434 scopus 로고    scopus 로고
    • National Heart, Lung, and Blood Institute. Accessed 8 September 2017
    • National Heart, Lung, and Blood Institute. What are the possible benefits and risks of clinical trials [Internet], 2017. Available from https://www. nhlbi. nih. gov/studies/clinicaltrials/benefitsrisks. Accessed 8 September 2017
    • (2017) What Are the Possible Benefits and Risks of Clinical Trials. [Internet]
  • 17
    • 85033221796 scopus 로고    scopus 로고
    • Harvard Women's HealthWatch, July Accessed 23 July 2016
    • Harvard Women's HealthWatch. What clinical studies can do for you [Internet], July 2012. Available from http://www. health. harvard. edu/ staying-healthy/what-clinical-studies-can-do-foryou. Accessed 23 July 2016
    • (2012) What Clinical Studies Can Do for You [Internet]
  • 20
    • 41549105366 scopus 로고    scopus 로고
    • Factors affecting therapeutic compliance: A review from the patient's perspective
    • Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review from the patient's perspective. Ther Clin Risk Manag 2008;4:269-286
    • (2008) Ther Clin Risk Manag , vol.4 , pp. 269-286
    • Jin, J.1    Sklar, G.E.2    Min Sen Oh, V.3    Chuen Li, S.4
  • 21
    • 85033228169 scopus 로고    scopus 로고
    • Understanding the gap between efficacy in randomized controlled trials and effectiveness in real-world use of GLP-1 RA and DPP-4 therapies in patients with type 2 diabetes
    • Carls GS, Tuttle E, Tan R-D, et al. Understanding the gap between efficacy in randomized controlled trials and effectiveness in real-world use of GLP-1 RA and DPP-4 therapies in patients with type 2 diabetes. Diabetes Care 2017;40:1469-1478
    • (2017) Diabetes Care , vol.40 , pp. 1469-1478
    • Carls, G.S.1    Tuttle, E.2    Tan, R.-D.3
  • 22
    • 77952309372 scopus 로고    scopus 로고
    • Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial
    • 1860-LIRA-DPP-4 Study Group
    • Pratley RE, Nauck M, Bailey T, et al.; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-1456
    • (2010) Lancet , vol.375 , pp. 1447-1456
    • Pratley, R.E.1    Nauck, M.2    Bailey, T.3
  • 23
    • 62449129181 scopus 로고    scopus 로고
    • Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)
    • LEAD-1 SU study group
    • Marre M, Shaw J, Brändle M, et al.; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-278
    • (2009) Diabet Med , vol.26 , pp. 268-278
    • Marre, M.1    Shaw, J.2    Brändle, M.3
  • 24
    • 62449169287 scopus 로고    scopus 로고
    • Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
    • LEAD-2 Study Group
    • NauckM, Frid A, Hermansen K, et al.; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009;32:84-90
    • (2009) Diabetes Care , vol.32 , pp. 84-90
    • Nauck, M.1    Frid, A.2    Hermansen, K.3
  • 25
    • 77953859640 scopus 로고    scopus 로고
    • Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial
    • DiamantM, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial. Lancet 2010;375:2234-2243
    • (2010) Lancet , vol.375 , pp. 2234-2243
    • Diamant, M.1    Van Gaal, L.2    Stranks, S.3
  • 26
    • 79955661908 scopus 로고    scopus 로고
    • DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes
    • Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301-1310
    • (2011) J Clin Endocrinol Metab , vol.96 , pp. 1301-1310
    • Blevins, T.1    Pullman, J.2    Malloy, J.3
  • 27
    • 59449101432 scopus 로고    scopus 로고
    • Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, doubleblind, parallel-treatment trial
    • LEAD-3 (Mono) Study Group
    • Garber A, Henry R, Ratner R, et al.; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, doubleblind, parallel-treatment trial. Lancet 2009;373: 473-481
    • (2009) Lancet , vol.373 , pp. 473-481
    • Garber, A.1    Henry, R.2    Ratner, R.3
  • 28
    • 67650066860 scopus 로고    scopus 로고
    • Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)
    • LEAD-4 Study Investigators
    • Zinman B, Gerich J, Buse JB, et al.; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-1230
    • (2009) Diabetes Care , vol.32 , pp. 1224-1230
    • Zinman, B.1    Gerich, J.2    Buse, J.B.3
  • 29
    • 33846817233 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patientswith type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial
    • Sitagliptin Study 024 Group
    • Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patientswith type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205
    • (2007) Diabetes Obes Metab , vol.9 , pp. 194-205
    • Nauck, M.A.1    Meininger, G.2    Sheng, D.3    Terranella, L.4    Stein, P.P.5
  • 30
    • 69549135336 scopus 로고    scopus 로고
    • The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone
    • Saxagliptin 014 Study Group
    • DeFronzo RA, Hissa MN, Garber AJ, et al.; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-1655
    • (2009) Diabetes Care , vol.32 , pp. 1649-1655
    • DeFronzo, R.A.1    Hissa, M.N.2    Garber, A.J.3
  • 31
    • 78650656671 scopus 로고    scopus 로고
    • Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: A randomized, double-blind, non-inferiority trial
    • Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011;13:160-168
    • (2011) Diabetes Obes Metab , vol.13 , pp. 160-168
    • Arechavaleta, R.1    Seck, T.2    Chen, Y.3
  • 32
    • 78349292168 scopus 로고    scopus 로고
    • Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: A 52-week randomised controlled trial
    • D1680C00001 Investigators
    • Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I; D1680C00001 Investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: A 52-week randomised controlled trial. Int J Clin Pract 2010;64:1619-1631
    • (2010) Int J Clin Pract , vol.64 , pp. 1619-1631
    • Göke, B.1    Gallwitz, B.2    Eriksson, J.3    Hellqvist, A.4    Gause-Nilsson, I.5
  • 33
    • 84862152967 scopus 로고    scopus 로고
    • Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: Meta-analysis and systematic review
    • Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012;34:1247-1258. e22
    • (2012) Clin Ther , vol.34 , pp. 1247-1258e22
    • Aroda, V.R.1    Henry, R.R.2    Han, J.3
  • 34
    • 85033227233 scopus 로고    scopus 로고
    • Centers for Medicare & Medicaid Services. Accessed 22 November 2016
    • Centers for Medicare & Medicaid Services. Medicare 2016 Part C & D star rating technical notes (draft) [Internet], 2015. Available from https://www. cms. gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovGenIn/ Downloads/2016-Technical-Notes-Preview-1-v2015-08-05. pdf. Accessed 22 November 2016
    • (2015) Medicare 2016 Part C & D Star Rating Technical Notes (Draft) [Internet]
  • 35
    • 64549094715 scopus 로고    scopus 로고
    • Diabetic patients' medication underuse, illness outcomes, and beliefs about antihyperglycemic and antihypertensive treatments
    • Aikens JE, Piette JD. Diabetic patients' medication underuse, illness outcomes, and beliefs about antihyperglycemic and antihypertensive treatments. Diabetes Care 2009;32:19-24
    • (2009) Diabetes Care , vol.32 , pp. 19-24
    • Aikens, J.E.1    Piette, J.D.2
  • 36
    • 84919845727 scopus 로고    scopus 로고
    • Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus
    • Farr AM, Sheehan JJ, Curkendall SM, Smith DM, Johnston SS, Kalsekar I. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus. Adv Ther 2014;31:1287-1305
    • (2014) Adv Ther , vol.31 , pp. 1287-1305
    • Farr, A.M.1    Sheehan, J.J.2    Curkendall, S.M.3    Smith, D.M.4    Johnston, S.S.5    Kalsekar, I.6
  • 37
    • 84936928911 scopus 로고    scopus 로고
    • Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: A retrospective cohort study
    • Buysman EK, Liu F, Hammer M, Langer J. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: A retrospective cohort study. Adv Ther 2015;32: 341-355
    • (2015) Adv Ther , vol.32 , pp. 341-355
    • Buysman, E.K.1    Liu, F.2    Hammer, M.3    Langer, J.4
  • 38
    • 85033232981 scopus 로고    scopus 로고
    • Treatment utilization patterns of GLP-1 agonists and DPP-4 inhibitors among type 2 diabetics in a U.S. Commercially insured population: 2005-2011. Poster (1589-P
    • 21-25 June 2013, Chicago, IL
    • Koro CE, Chhabra P, Stender M, Spain CV, Allen JK, Krzywy HJ. Treatment utilization patterns of GLP-1 agonists and DPP-4 inhibitors among type 2 diabetics in a U. S. commercially insured population: 2005-2011. Poster (1589-P) presented at the 73rd Scientific Sessions of the American Diabetes Association, 21-25 June 2013, Chicago, IL
    • The 73rd Scientific Sessions of the American Diabetes Association
    • Koro, C.E.1    Chhabra, P.2    Stender, M.3    Spain, C.V.4    Allen, J.K.5    Krzywy, H.J.6
  • 39
    • 38549098101 scopus 로고    scopus 로고
    • Medication compliance and persistence: Terminology and definitions
    • Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: Terminology and definitions. Value Health 2008;11:44-47
    • (2008) Value Health , vol.11 , pp. 44-47
    • Cramer, J.A.1    Roy, A.2    Burrell, A.3
  • 40
    • 85033228497 scopus 로고    scopus 로고
    • Comparative persistence with antihyperglycemic agents used to treat type 2 diabetes mellitus in the real world
    • 10-14 June 2016, New Orleans, LA
    • Cai J, Wang Y, Baser O, et al. Comparative persistence with antihyperglycemic agents used to treat type 2 diabetes mellitus in the real world. Poster (1155-P) presented at the 76th Scientific Sessions of the American Diabetes Association, 10-14 June 2016, New Orleans, LA
    • 76th Scientific Sessions of the American Diabetes Association
    • Cai, J.1    Wang, Y.2    Baser, O.3
  • 41
    • 77951102841 scopus 로고    scopus 로고
    • Primary medication non-adherence: Analysis of 195, 930 electronic prescriptions
    • Fischer MA, Stedman MR, Lii J, et al. Primary medication non-adherence: Analysis of 195, 930 electronic prescriptions. J Gen Intern Med 2010; 25:284-290
    • (2010) J Gen Intern Med , vol.25 , pp. 284-290
    • Fischer, M.A.1    Stedman, M.R.2    Lii, J.3
  • 42
    • 33749006625 scopus 로고    scopus 로고
    • Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus
    • Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166: 1836-1841
    • (2006) Arch Intern Med , vol.166 , pp. 1836-1841
    • Ho, P.M.1    Rumsfeld, J.S.2    Masoudi, F.A.3
  • 43
    • 20544460816 scopus 로고    scopus 로고
    • Impact of medication adherence on hospitalization risk and healthcare cost
    • Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-530
    • (2005) Med Care , vol.43 , pp. 521-530
    • Sokol, M.C.1    McGuigan, K.A.2    Verbrugge, R.R.3    Epstein, R.S.4
  • 44
    • 84898678920 scopus 로고    scopus 로고
    • Longitudinal effects of medication nonadherence on glycemic control
    • Egede LE, Gebregziabher M, Echols C, Lynch CP. Longitudinal effects of medication nonadherence on glycemic control. Ann Pharmacother 2014;48:562-570
    • (2014) Ann Pharmacother , vol.48 , pp. 562-570
    • Egede, L.E.1    Gebregziabher, M.2    Echols, C.3    Lynch, C.P.4
  • 45
    • 84984991360 scopus 로고    scopus 로고
    • Associations between adherence and outcomes among older, type 2 diabetes patients: Evidence from a Medicare Supplemental database
    • Boye KS, Curtis SE, Lage MJ, Garcia-Perez LE. Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database. Patient Prefer Adherence 2016;10:1573-1581
    • (2016) Patient Prefer Adherence , vol.10 , pp. 1573-1581
    • Boye, K.S.1    Curtis, S.E.2    Lage, M.J.3    Garcia-Perez, L.E.4
  • 46
    • 84978839381 scopus 로고    scopus 로고
    • Liraglutide and cardiovascular outcomes in type 2 diabetes
    • LEADER Steering Committee; LEADER Trial Investigators
    • Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl JMed 2016;375: 311-322
    • (2016) N Engl JMed , vol.375 , pp. 311-322
    • Marso, S.P.1    Daniels, G.H.2    Brown-Frandsen, K.3
  • 47
    • 85033241313 scopus 로고    scopus 로고
    • Novo Nordisk drug cuts diabetic deaths, but not enough for Wall Street [article online]
    • 14 June. Accessed 18 July 2016
    • Reeves A. Novo Nordisk drug cuts diabetic deaths, but not enough for Wall Street [article online]. Investor's Business Daily, 14 June 2016. Available from http://www. investors. com/news/ technology/novo-nordisk-drug-cuts-diabeticdeaths-but-not-enough-for-street/. Accessed 18 July 2016
    • (2016) Investor's Business Daily
    • Reeves, A.1
  • 49
    • 0036361575 scopus 로고    scopus 로고
    • Physicianpatient communication in the primary care office: A systematic review
    • Beck RS, Daughtridge R, Sloane PD. Physicianpatient communication in the primary care office: A systematic review. J Am Board Fam Pract 2002; 15:25-38
    • (2002) J Am Board Fam Pract , vol.15 , pp. 25-38
    • Beck, R.S.1    Daughtridge, R.2    Sloane, P.D.3
  • 50
    • 68249138773 scopus 로고    scopus 로고
    • Physician communication and patient adherence to treatment: A meta-analysis
    • Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treatment: A meta-analysis. Med Care 2009;47:826-834
    • (2009) Med Care , vol.47 , pp. 826-834
    • Zolnierek, K.B.1    Dimatteo, M.R.2
  • 51
    • 70449677664 scopus 로고    scopus 로고
    • Cost-related nonadherence to medications among patients with diabetes and chronic pain: Factors beyond finances
    • Kurlander JE, Kerr EA, Krein S, Heisler M, Piette JD. Cost-related nonadherence to medications among patients with diabetes and chronic pain: factors beyond finances. Diabetes Care 2009;32:2143-2148
    • (2009) Diabetes Care , vol.32 , pp. 2143-2148
    • Kurlander, J.E.1    Kerr, E.A.2    Krein, S.3    Heisler, M.4    Piette, J.D.5
  • 52
    • 84868309875 scopus 로고    scopus 로고
    • Rethinking adherence
    • Steiner JF. Rethinking adherence. Ann Intern Med 2012;157:580-585
    • (2012) Ann Intern Med , vol.157 , pp. 580-585
    • Steiner, J.F.1
  • 53
    • 84923366744 scopus 로고    scopus 로고
    • A systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetesdimpact on adherence
    • Sapkota S, Brien JA, Greenfield J, Aslani P. A systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetesdimpact on adherence. PLoS One 2015;10:e0118296
    • (2015) PLoS One , vol.10 , pp. e0118296
    • Sapkota, S.1    Brien, J.A.2    Greenfield, J.3    Aslani, P.4
  • 54
    • 84855670216 scopus 로고    scopus 로고
    • An integrated pharmacy-based program improved medication prescription and adherence rates in diabetes patients
    • Brennan TA, Dollear TJ, Hu M, et al. An integrated pharmacy-based program improved medication prescription and adherence rates in diabetes patients. Health Aff (Millwood) 2012; 31:120-129
    • (2012) Health Aff (Millwood) , vol.31 , pp. 120-129
    • Brennan, T.A.1    Dollear, T.J.2    Hu, M.3
  • 55
    • 79957610344 scopus 로고    scopus 로고
    • Effectiveness of home telehealth in comorbid diabetes and hypertension: A randomized, controlled trial
    • Wakefield BJ, Holman JE, Ray A, et al. Effectiveness of home telehealth in comorbid diabetes and hypertension: A randomized, controlled trial. Telemed J E Health 2011;17:254-261
    • (2011) Telemed J e Health , vol.17 , pp. 254-261
    • Wakefield, B.J.1    Holman, J.E.2    Ray, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.